These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 15292057)

  • 1. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.
    Taylor PA; Panoskaltsis-Mortari A; Swedin JM; Lucas PJ; Gress RE; Levine BL; June CH; Serody JS; Blazar BR
    Blood; 2004 Dec; 104(12):3804-12. PubMed ID: 15292057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT.
    Johnson BD; Konkol MC; Truitt RL
    Biol Blood Marrow Transplant; 2002; 8(10):525-35. PubMed ID: 12434947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.
    Taylor PA; Lees CJ; Blazar BR
    Blood; 2002 May; 99(10):3493-9. PubMed ID: 11986199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.
    Drobyski WR; Gendelman M
    Leuk Lymphoma; 2002 Oct; 43(10):2011-6. PubMed ID: 12481900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.
    Hanash AM; Levy RB
    Blood; 2005 Feb; 105(4):1828-36. PubMed ID: 15494429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G; Kovochich M; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice.
    Fowler DH; Kurasawa K; Smith R; Eckhaus MA; Gress RE
    Blood; 1994 Nov; 84(10):3540-9. PubMed ID: 7949109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD.
    Ermann J; Hoffmann P; Edinger M; Dutt S; Blankenberg FG; Higgins JP; Negrin RS; Fathman CG; Strober S
    Blood; 2005 Mar; 105(5):2220-6. PubMed ID: 15546950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease by intrabone marrow injection of donor T cells: involvement of bone marrow stromal cells.
    Miyake T; Inaba M; Fukui J; Ueda Y; Hosaka N; Kamiyama Y; Ikehara S
    Clin Exp Immunol; 2008 Apr; 152(1):153-62. PubMed ID: 18307515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.
    Semple K; Yu Y; Wang D; Anasetti C; Yu XZ
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):309-18. PubMed ID: 21224010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of clinical GVHD and the in vivo induction of regulatory T cells after transplantation of facilitating cells.
    Colson YL; Christopher K; Glickman J; Taylor KN; Wright R; Perkins DL
    Blood; 2004 Dec; 104(12):3829-35. PubMed ID: 15297318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
    Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.